[go: up one dir, main page]

WO2024233847A3 - Composés hétérocycliques utilisés en tant que récepteur de déclenchement exprimé sur des agonistes de cellules myéloïdes 2 et procédés d'utilisation - Google Patents

Composés hétérocycliques utilisés en tant que récepteur de déclenchement exprimé sur des agonistes de cellules myéloïdes 2 et procédés d'utilisation Download PDF

Info

Publication number
WO2024233847A3
WO2024233847A3 PCT/US2024/028688 US2024028688W WO2024233847A3 WO 2024233847 A3 WO2024233847 A3 WO 2024233847A3 US 2024028688 W US2024028688 W US 2024028688W WO 2024233847 A3 WO2024233847 A3 WO 2024233847A3
Authority
WO
WIPO (PCT)
Prior art keywords
myeloid cells
receptor expressed
agonists
methods
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/028688
Other languages
English (en)
Other versions
WO2024233847A2 (fr
Inventor
Jonathan B. Houze
Bhaumik PANDYA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vigil Neuroscience Inc
Original Assignee
Vigil Neuroscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vigil Neuroscience Inc filed Critical Vigil Neuroscience Inc
Publication of WO2024233847A2 publication Critical patent/WO2024233847A2/fr
Publication of WO2024233847A3 publication Critical patent/WO2024233847A3/fr
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés utiles pour l'activation du récepteur de déclenchement exprimé sur des cellules myéloïdes 2 ("TREM2"). La présente invention concerne également des compositions pharmaceutiques comprenant les composés, des utilisations des composés, et des compositions pour le traitement, par exemple, d'un trouble neurodégénératif. En outre, l'invention concerne des intermédiaires utiles dans la synthèse de composés de formule I.
PCT/US2024/028688 2023-05-10 2024-05-09 Composés hétérocycliques utilisés en tant que récepteur de déclenchement exprimé sur des agonistes de cellules myéloïdes 2 et procédés d'utilisation Pending WO2024233847A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363501392P 2023-05-10 2023-05-10
US63/501,392 2023-05-10

Publications (2)

Publication Number Publication Date
WO2024233847A2 WO2024233847A2 (fr) 2024-11-14
WO2024233847A3 true WO2024233847A3 (fr) 2025-05-15

Family

ID=93431101

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/028688 Pending WO2024233847A2 (fr) 2023-05-10 2024-05-09 Composés hétérocycliques utilisés en tant que récepteur de déclenchement exprimé sur des agonistes de cellules myéloïdes 2 et procédés d'utilisation

Country Status (1)

Country Link
WO (1) WO2024233847A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12459952B2 (en) 2024-01-04 2025-11-04 Muna Therapeutics Aps TREM2 modulators
US12459953B2 (en) 2024-01-04 2025-11-04 Muna Therapeutics Aps TREM2 modulators

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677352B1 (en) * 2001-09-26 2004-01-13 Yamin Wang 1,6-naphthyridine derivatives and their use to treat diabetes and related disorders
WO2009097287A1 (fr) * 2008-02-01 2009-08-06 Irm Llc Composés et compositions comme inhibiteurs de kinases
US10548899B2 (en) * 2015-10-20 2020-02-04 Takeda Pharmaceutical Company Limited Quinazolinone and benzotriazinone compounds with cholinergic muscarinin M1 receptor positive allosteric modulator activity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677352B1 (en) * 2001-09-26 2004-01-13 Yamin Wang 1,6-naphthyridine derivatives and their use to treat diabetes and related disorders
WO2009097287A1 (fr) * 2008-02-01 2009-08-06 Irm Llc Composés et compositions comme inhibiteurs de kinases
US10548899B2 (en) * 2015-10-20 2020-02-04 Takeda Pharmaceutical Company Limited Quinazolinone and benzotriazinone compounds with cholinergic muscarinin M1 receptor positive allosteric modulator activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE Compound 8 February 2007 (2007-02-08), "5,8-dimethyl-6-(triazolo[4,5-c]pyridin-1-yl)-2H-isoquinolin-1-one", XP093326386, Database accession no. 12831685 *

Also Published As

Publication number Publication date
WO2024233847A2 (fr) 2024-11-14

Similar Documents

Publication Publication Date Title
PH12022552949A1 (en) Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
PH12022552933A1 (en) Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
WO2022236272A3 (fr) Composés hétérocycliques utilisés en tant que récepteur de déclenchement exprimé sur des agonistes de cellules myéloïdes 2 et procédés d'utilisation
US12213965B2 (en) Riluzole prodrugs and their use
WO2024233847A3 (fr) Composés hétérocycliques utilisés en tant que récepteur de déclenchement exprimé sur des agonistes de cellules myéloïdes 2 et procédés d'utilisation
MX2007007220A (es) Compuestos de pirazolona como agonistas de receptor de glutamato metabotropico para el tratamiento de trastornos neurologicos y psiquiatricos.
ES2977656T3 (es) Inhibidores de KDM1A para el tratamiento de enfermedades
AU2021323253A8 (en) Heterocyclic GLP-1 agonists
UA85576C2 (ru) Тетразольные соединения и их применение в качестве метаботропических антагонистов рецепторов глутамата
IL177291A0 (en) Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists
MXPA05010824A (es) Compuestos biciclicos como antagonistas del receptor nr2b.
WO2024008722A3 (fr) Modulateurs de trem2
EP1725536B8 (fr) Derives de l'imidazoline presentant une activite antagoniste cb1
MX2025002166A (es) Compuestos y metodos para modular her2
WO2021224680A8 (fr) Métabolites de benzotriazinone substitués d'un agoniste gpr139
CA3156320A1 (fr) Derives de 2-azaspiro[3,4] octane utilises en tant qu'agonistes de m4
PH12022550860A1 (en) 5-oxa-2-azaspiro[3.4]octane derivatives as m4 agonists
US20220396555A1 (en) Prodrugs of riluzole and their method of use
EP4599849A3 (fr) Nouveaux inhibiteurs de l'autotaxine
RU2813145C2 (ru) Ингибиторы лизинспецифической гистондеметилазы 1A (KDM1A) для терапии заболеваний
MX2025013377A (es) Amidas biciclicas 5,6-condensadas y composiciones para su uso como moduladores de la 15-prostaglandina deshidrogenasa
MX2025013369A (es) Alcoholes y eteres biciclicos 5,6-condensados y 6,6-condensados y composiciones para su uso como moduladores de la 15-prostaglandina deshidrogenasa
UA84737C2 (ru) Производные имидазолина с антагонистической активностью относительно cb1
MY136600A (en) Compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24804298

Country of ref document: EP

Kind code of ref document: A2